Rule of Prevention: a potential framework to evaluate preventive interventions for rare diseases

References

• Lakdawalla DN, Doshi JA, Garrison LP, et al. Defining elements of value in health care—a health economics approach: an ISPOR special task force report [3]. Value Health. 2018;21(2):131–11. doi: 10.1016/j.jval.2017.12.007
   PubMed Web of Science ®Google Scholar
• Angelis A, Kanavos P, Montibeller G. Resource allocation and priority setting in health care: a multi-criteria decision analysis problem of value? Global Policy. 2017;8(S2):76–83. doi: 10.1111/1758-5899.12387
   Google Scholar
• Gustavsson E, Tinghög G. Needs and cost-effectiveness in health care priority setting. Health Technol. 2020;10(3):611–619. doi: 10.1007/s12553-020-00424-7
   Web of Science ®Google Scholar
• World Health Organization (WHO). Strategizing national health in the 21st century: a handbook - Priority-setting for national health policies, strategies and plans (Chapter 4) 2016 [Cited: 2022 June 16]. Available from: https://apps.who.int/iris/bitstream/handle/10665/250221/9789241549745-chapter4-eng.pdf;jsessionid=AA42AFA70BCBE0D49F850FA2DC5F7311?sequence=36.
   Google Scholar
• Reckers-Droog V, van Exel J, Brouwer W. Equity weights for priority setting in healthcare: severity, age, or both? Value Health. 2019;22(12):1441–1449. doi: 10.1016/j.jval.2019.07.012
   PubMed Web of Science ®Google Scholar
• Charlton V. Does NICE apply the rule of rescue in its approach to highly specialised technologies? J Med Ethics. 2022 Feb;48(2):118–125. doi: 10.1136/medethics-2020-106759
   PubMed Web of Science ®Google Scholar
• Cookson R, McCabe C, Tsuchiya A. Public healthcare resource allocation and the rule of rescue. J Med Ethics. 2008;34(7):540–544. doi: 10.1136/jme.2007.021790
   PubMed Web of Science ®Google Scholar
• Blonda A, Denier Y, Huys I, et al. how to value orphan drugs? A review of European value assessment frameworks. Front Pharmacol. 2021;12:631527. doi: 10.3389/fphar.2021.631527
   PubMed Web of Science ®Google Scholar
• Nicod E, Whittal A, Drummond M, et al. Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches. Orphanet J Rare Dis. 2020 Jul 20;15(1):189. doi: 10.1186/s13023-020-01462-0
   PubMed Web of Science ®Google Scholar
• Frederiksen SD, Avramović V, Maroilley T, et al. Rare disorders have many faces: in silico characterization of rare disorder spectrum. Orphanet J Rare Dis. 2022 Feb 22;17(1):76.
   PubMed Web of Science ®Google Scholar
• Shen J, Begum N, Ruiz-Garcia Y, et al. Range of invasive meningococcal disease sequelae and health economic application - a systematic and clinical review. BMC Public Health. 2022 May 31;22(1):1078. doi: 10.1186/s12889-022-13342-2
   PubMed Web of Science ®Google Scholar
• Guedes S, Bricout H, Langevin E, et al. Epidemiology of invasive meningococcal disease and sequelae in the United Kingdom during the period 2008 to 2017 - a secondary database analysis. BMC Public Health. 2022;22(1). doi: 10.1186/s12889-022-12933-3
   Web of Science ®Google Scholar
• Davis K, Misurski D, Miller J, et al. Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Hum Vaccines. 2011;7(4):458–465. doi: 10.4161/hv.7.4.14434
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter CL, Hickman M, et al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014 Oct 9;349:5725. doi: 10.1136/bmj.g5725
   Google Scholar
• National Organization for Rare Disorders (NORD). Meningococcal meningitis [Cited: 2022 June 21]. Available from: https://rarediseases.org/rare-diseases/meningococcal-meningitis/.
   Google Scholar
• Royal College of Nursing. Immunisation: Royal College of Nursing; 2021 [Cited: 2022 June 21]. Available from: https://www.rcn.org.uk/clinical-topics/public-health/immunisation.
   Google Scholar
• Public Health England (PHE). Reducing unintentional injuries on the roads among children and young people under 25 years 2018 [Cited: 2022 June 21]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/695781/Reducing_unintentional_injuries_on_the_roads_among_children_and_young_people_.pdf.
   Google Scholar
• Levine S, Malone E, Lekiachvili A, et al. Health care industry insights: Why the use of preventive services is still low. Prev Chronic Dis. 2019;16. doi: 10.5888/pcd16.180625.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Majority of US adults are missing routine vaccinations 2021 [ Cited: 01-06-2023]. Available from: https://www.cdc.gov/vaccines/hcp/adults/for-practice/increasing-vacc-rates.html.
   Google Scholar
• SocialFinance.org. Why don’t we fund more prevention? 2019 [ Cited: 01-06-2023]. Available from: https://socialfinance.org/insight/why-dont-we-fund-more-prevention/.
   Google Scholar
• Stephen M, James L, Karl C. Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity. BMJ Open. 2020;10(10):e036411. doi: 10.1136/bmjopen-2019-036411
   PubMed Web of Science ®Google Scholar
• Talic S, Shah S, Wild H, et al. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and COVID-19 mortality: systematic review and meta-analysi. BMJ. 2021;375(68302):e068302. doi: 10.1136/bmj-2021-068302
   PubMedGoogle Scholar
• Mykhalovskiy E, French M. COVID-19, public health, and the politics of prevention. Sociology Of Health And Illness. 2020;42(8):4–15. doi: 10.1111/1467-9566.13192
   PubMed Web of Science ®Google Scholar
• Dabbous O, Chachoua L, Aballéa S, et al. Valuation of treatments for rare diseases: a systematic literature review of societal preference studies. Adv Ther. 2023 Feb;40(2):393–424.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Changes we’re making to health technology evaluation 2022 [Cited: 2022 June 21]. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Centre for health technology evaluation (CHTE) methods review - Developing the manual, Task and finish group report 2021 [Cited: 2022 April 22]. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/nice-guidance/chte-methods-and-processes-consultation/developing-the-manual-tfg-report.docx.
   Google Scholar
• Skedgel C, Henderson N, Towse A, et al. Considering severity in health technology assessment: can we do better? Value Health. 2022 Aug 01;25(8):1399–1403.
   PubMed Web of Science ®Google Scholar
• Taha MK, Martinon-Torres F, Köllges R, et al. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Rev Vaccines. 2022 Mar;29:1–16.
   Google Scholar
• Oliver S ACIP COVID-19 vaccines. EtR framework: Public health problem, resource use and equity domains 2020 [Cited: 2022 April 22]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-11/COVID-02-Oliver.pdf.
   Google Scholar
• Jit M, Hutubessy R, En Png M, et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med. 2015;13(209):1–9. doi: 10.1186/s12916-015-0446-9
   PubMedGoogle Scholar
• Postma M, Biundo E, Chicoye A, et al. Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts. Vaccine. 2022 Jun 26;40(30):3999–4007. doi: 10.1016/j.vaccine.2022.04.026
   PubMed Web of Science ®Google Scholar
• Bonanni P, Picazo JJ, Rémy V. The intangible benefits of vaccination – what is the true economic value of vaccination? J Mark Access Health Policy. 2015;3:3. doi: 10.3402/jmahp.v3.26964
   Google Scholar
• Doherty MT, Aris E, Servotte N, et al. Capturing the value of vaccination: impact of vaccine-preventable disease on hospitalization. Aging Clin Exp Res. 2022 July 01;34(7):1551–1561.
   PubMed Web of Science ®Google Scholar
• Bärnighausen T, Bloom DE, Cafiero ET, et al. Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus. Clin Microbiol Infect. 2012 Oct;18(5):70–76.
   PubMedGoogle Scholar
• Beck E, Biundo E, Devlin N, et al. Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework. Vaccine. 2022 Jun 26;40(30):4008–4016. doi: 10.1016/j.vaccine.2022.04.050
   PubMed Web of Science ®Google Scholar
• Sumpter R, Brunklaus M, McWilliam R, et al. Health-related quality-of-life and behavioural outcome in survivors of childhood meningitis. Brain Inj. 2011;25(13–14):1288–1295. doi: 10.3109/02699052.2011.613090
   PubMed Web of Science ®Google Scholar
• Al-Janabi H, Van Exel J, Brouwer W, et al. Measuring Health Spillovers for Economic Evaluation: A Case Study in Meningitis. Health Econ. 2016;25(12):1529–1544. doi: 10.1002/hec.3259
   PubMed Web of Science ®Google Scholar
• Olbrich K, Muller D, Schumacher S, et al. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421–438. doi: 10.1007/s40121-018-0213-2
   PubMed Web of Science ®Google Scholar
• Shen J, Bouée S, Aris E, et al. Long-term mortality and state financial support in invasive meningococcal disease-real-world data analysis using the French national claims database (SNIIRAM). Infect Dis Ther. 2022 Feb;11(1):249–262.
   PubMed Web of Science ®Google Scholar
• Sevilla J, Tortorice D, Kantor D, et al. editors. Lifecycle model-based economic evaluation of infant meningitis B vaccination in the UK. Copenhagen: ISPOR; 2019.
   Google Scholar
• Beck E, Klint J, Neine M, et al. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup b invasive meningococcal disease. Value Health. 2021;24(1):91–104. doi: 10.1016/j.jval.2020.09.004
   PubMed Web of Science ®Google Scholar
• Dronova M, Biundo E, Chicoye A, et al. editors. The value of vaccination: capturing the impact of vaccination on health equity in health economic analysis. Vienna Austria: ISPOR Europe; 2022.
   Google Scholar
• Martinón-Torres F, Trilla A. Meningococcal disease: Can we predict the unpredictable? Med Clin. 2020 Jan 10;154(1):20–22. doi: 10.1016/j.medcli.2019.04.035
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter CL, Hickman M, et al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014 Oct 9;349(oct09 4):g5725. doi: 10.1136/bmj.g5725
   PubMedGoogle Scholar
• Christensen H, Al-Janabi H, Levy P, et al. Economic evaluation of meningococcal vaccines: considerations for the future. Eur J Health Econ. 2020;21(2):297–309. doi: 10.1007/s10198-019-01129-z
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Masaquel C, Huang L. Evaluating vaccination programs that prevent diseases with potentially catastrophic health outcomes: how can we capture the value of risk reduction? Value Health. 2021;24(1):86–90. doi: 10.1016/j.jval.2020.06.018
   PubMed Web of Science ®Google Scholar
• Linley WG, Hughes DA. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ. 2013;22(8):948–964. doi: 10.1002/hec.2872
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Chapman RH, Pearson SD. Evaluating and valuing drugs for rare diseases: no easy answers. Value Health. 2018;21:547–557. doi: 10.1016/j.jval.2018.01.008
   PubMed Web of Science ®Google Scholar
• Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42. doi: 10.1017/S0266462307051550
   PubMed Web of Science ®Google Scholar
• Nicod E, Anneman L, Bucsics A, et al. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries. Health Policy. 2019;123(2):140–151. doi: 10.1016/j.healthpol.2017.03.009
   PubMed Web of Science ®Google Scholar
• NHS. NHS UK 2021 [Cited: 2022 June 6]. Available from: https://www.england.nhs.uk/2021/07/nhs-england-announces-new-innovative-medicines-fund-to-fast-track-promising-new-drugs/.
   Google Scholar
• Mayor S. New “managed access” process for cancer drugs fund to go ahead, NHS England confirms. BMJ. 2016;352. doi: 10.1136/bmj.i1208
   Google Scholar
• Jonsen AR. Bentham in a box: technology assessment and health care allocation. L Med Health Care. 1986;14(3–4):172–174. doi: 10.1111/j.1748-720X.1986.tb00974.x
   PubMedGoogle Scholar
• Goebbels AF, Ament AJ, Novák A, et al. Estimating the implicit value of statistical life based on public interventions implemented in the Netherlands. Int J Technol Assess Health Care. 2008 Fall;24(4):495–501.doi: 10.1017/S0266462308080653.
   PubMed Web of Science ®Google Scholar
• Laigle V, Postma MJ, Pavlovic M, et al. Vaccine market access pathways in the EU27 and the United Kingdom -analysis and recommendations for improvements. Vaccine. 2021 Sep 15;39(39):5706–5718. doi: 10.1016/j.vaccine.2021.07.040
   PubMed Web of Science ®Google Scholar